Conferences > OncoLink Scientific Meetings Coverage > OncoLink at the San Antonio Breast Cancer Symposium 2006 > Highlights from SABCS 2006

OncoLink reporters provide in-depth coverage of scientific presentations from the 29^th Annual San Antonio Breast Cancer Symposium.

OncoLink Professor On-Call: Lawrence Solin, MD provides exclusive expert review and insights from the recent San Antonio Breast Cancer Symposia for OncoLink

Axillary lymph node nanometastases are prognostic factors for metastatic relapse in breast cancer patients

Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33

The Breast Cancer Epigenome

Combined Clinical Trial Results Of A HER2/Neu (E75) Vaccine For Prevention Of Recurrence In High-Risk Breast Cancer Patients

Five year results of Intergroup Study E5194: local excision alone (without radiation treatment) for selected patients with ductal carcinoma in situ (DCIS)

Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: first results from EFFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer

Impact of radiation dose on local control, fibrosis and survival after breast conserving treatment: 10 years results of the EORTC trial 22881-10882

Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer: a report of further follow-up

A Sharp Decrease In Breast Cancer Incidence In The United States In 2003